Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety roll-over study of Tafinlar (dabrafenib) and Mekinist (trametinib)
2023-509318-13-00Phase 4Authorised
- Sponsor
- Novartis
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 4, open-label trial of dabrafenib + trametinib and trametinib in Nonhematologic neoplasms, melanoma and Neoplasm (3 arms), sponsored by Novartis. Primary endpoint: Frequency and severity of AEs/SAEs. Planned start Jan 2018; status: authorised.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
Nonhematologic neoplasmsmelanomaNeoplasm
Beyond the preview
Go deeper on 2023-509318-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509318-13-00.